Bayesian Enrichment Strategies for Randomized Discontinuation Trials

Biometrics

Volumn 68, Issue 1, 2012, Pages 203-211

  Trippa, Lorenzo ^a   Rosner, Gary L ^b   Müller, Peter ^c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Clinical trials; Enrichment designs; Randomized discontinuation design; Tumor growth models

Indexed keywords

PATIENT TREATMENT; RANDOM PROCESSES;

BAYESIAN; BAYESIAN DECISION; CLINICAL TRIAL; DESIGN PARAMETERS; ENRICHMENT DESIGN; OPTIMAL CHOICE; RANDOMISATION; RANDOMIZED DISCONTINUATION DESIGN; TUMOR GROWTH MODELING; TUNING PARAMETER;

TUMORS;

BAYESIAN ANALYSIS; BIOMETRY; DECISION ANALYSIS; DESIGN; NUMERICAL MODEL; PUBLIC HEALTH; SUBPOPULATION; TUMOR;

EID: 84858864984     PISSN: 0006341X     EISSN: 15410420     Source Type: Journal    
DOI: 10.1111/j.1541-0420.2011.01623.x     Document Type: Article

References (29)

1. Albano, G. and Giorno, V. (2006). A stochastic model in tumor growth. Journal of Theoretical Biology 241, 329-336.
2. Albano, G. and Giorno, V. (2009). On the first exit time problem for a Gompertz-type tumor growth. Lecture Notes in Computer Science 5717, 329-336.
3. Bursham, K. P. and Anderson, D. R. (1998). Model Selection and Inference. New York: Springer-Verlag.
4. Capra, W. (2004). Comparing the power of the discontinuation design to that of the classic randomized design on time-to-event endpoints. Controlled Clinical Trials 25, 168-177.
5. Clare, S., Nakhlis, F., and Panetta, J. (2000). Molecular biology of breast metastasis: The use of mathematical models to determine relapse and to predict response to chemotherapy in breast cancer. Breast Cancer Research 2, 430-435.
6. DeGroot, M. (2004). Optimal Statistical Decisions. New York: Wiley Interscience.
7. Fedorov, F. and Liu, T. (2005). Randomized discontinuation trials: Design and efficiency. Technical Report. Collegeville, Pennsylvania: Glaxo Smith Kline
8. Ferrante, L., Bompadre, S., Possati, L., and Leone, L. (2000). Parameter estimation in a Gompertzian stochastic model for tumor growth. Biometrics 56, 1076-1081.
9. Freidlin, B. and Simon, R. (2005). Evaluation of randomized discontinuation design. Journal of Clinical Oncology 23, 5094-5098.
10. Fu, P., Dowlati, A., and Shluchter, M. (2009). Comparison of power between randomized discontinuation design and upfront randomization design on progression-free survival. Journal of Clinical Oncology 27, 4135-4141.
11. Galsky, M. D., Zaks, T., Hassani, H, Vocila, L., Sonpavde, G., Hutson, T. E., and Von Hoff, D. D. (2009). Target specific randomized discontinuation trial design: A novel approach in molecular therapeutics. Investigational New Drugs 28, 194-198.
12. Garthwaite, P. H., Kadane, J. B., and O'Hagan, A. (2005). Statistical methods for eliciting probability distributions. Journal of the American Statistical Association 100, 680-701.
13. Gutiérrez, R., Gutiérrez-Sáncheza, R., Nafidia, A., and Ramosa, E. (2006). A new stochastic Gompertz diffusion process with threshold parameter: Computational aspects and applications. Applied Mathematics and Computation 183, 738-747.
14. Korn, E. L., Arbuck, S. G., Pluda, J. M., Simon, R., Kaplan, R. S., and Christian, M. C. (2001). Clinical trial designs for cytostatic agents: Are new approaches needed? Journal of Clinical Oncology 19, 265-272.
15. Larkin, J. M. G., Kipps, E. L. S., Powell, C. J., and Swanton, C. (2009). Systemic therapy for advanced renal cell carcinoma. Therapeutic Advances in Medical Oncology 1, 15-27.
16. Levy, H. (1973). Stochastic dominance among log-normal prospects. International Economic Review 14, 601-614.
17. Millar, A. W. and Lynch, K. P. (2003). Rethinking clinical trials for cytostatic drugs. Nature Reviews Cancer 3, 540-545.
18. Müller, P. and Parmigiani, G. (1995). Optimal design via curve fitting of Monte Carlo experiments. Journal of the American Statistical Association 90, 1322-1330.
19. Nestorov, I., Graham, G., Duffull, S., Aarons, L., Fuseau, E., and Coates, P. (2001). Modeling and simulation for clinical trial design involving a categorical response: A phase II case study with Naratriptan. Pharmaceutical Research 18, 1210-1219.
20. Padgett, W. and Wei, L. J. (1977). Bayes estimation of reliability for the two-parameter lognormal distribution. Communications in Statistics 6, 443-457.
21. Ratain, M. J., Eisen, T., Stadler, W. M., Flaherty, K. T., Kaye, S. B., Rosner, G. L., Gore, M., Desai, A. A., Patnaik, A., Xiong, H. Q., Rowinsky, E., Abbruzzese, J. L., Xia, C., Simantov, R., Schwartz, B., and O'Dwyer, P. J. (2006). Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology 24, 2505-2512.
22. Ribba, B., Saut, O., Colin, T., Bresch, D., Grenier, E., and Boissel, J. P. (2006). A multiscale mathematical model of avascular tumor growth to investigate the therapeutic benefit of anti-invasive agents. Journal of Theoretical Biology 243, 532-541.
23. Rosner, G. L., Stadler, W., and Ratain, M. J. (2002). Randomized discontinuation design: Application to cytostatic antineoplastic agents. Journal of Clinical Oncology 20, 4478-4484.
24. Schnatter, S. and Kaufmann, S. (2008). Model-based clustering of multiple time series. Journal of Business and Economic Statistics 26, 78-89.
25. Stadler, W. M. (2007). The randomized discontinuation trial: A phase II design to assess growth-inhibitory agents. Molecular Cancer Therapeutics 6, 1180-1185.
26. Stadler, W. M. (2009). Other paradigms: Randomized discontinuation trial design. The Cancer Journal 15, 431-434.
27. Stadler, W. M., Rosner, G., Small, E., Hollis, D., Rini, B., Zaentz, S. D., Mahoney, J., and Ratain, M. J. (2005). Successful implementation of the randomized discontinuation trial design: An application to the study of the putative antiangiogenic agent carboxyaminoimidazole in renal cell carcinoma-CALGB 69901. Journal of Clinical Oncology 23, 3726-3732.
28. Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., and Gwyther, S. G. (2000). New guidelines to evaluate the response to treatment in solid tumors. Journal of the National Cancer Institute 92, 205-216.
29. Waliszewski, P. (2005). A principle of fractal-stochastic dualism and Gompertzian dynamics of growth and self-organization. Biosystems 82, 61-73.